Westchester Capital Management Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 188,331 shares of the biopharmaceutical company’s stock after buying an additional 1,825 shares during the period. Pfizer accounts for approximately 2.9% of Westchester Capital Management Inc.’s holdings, making the stock its 25th largest position. Westchester Capital Management Inc.’s holdings in Pfizer were worth $6,631,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. GW&K Investment Management LLC raised its position in shares of Pfizer by 4.6% in the first quarter. GW&K Investment Management LLC now owns 959,019 shares of the biopharmaceutical company’s stock worth $28,425,000 after buying an additional 41,757 shares during the last quarter. Kelman Lazarov Inc. bought a new position in Pfizer during the first quarter valued at approximately $501,000. Oliver Luxxe Assets LLC raised its position in Pfizer by 429.0% in the first quarter. Oliver Luxxe Assets LLC now owns 100,305 shares of the biopharmaceutical company’s stock valued at $2,973,000 after buying an additional 81,343 shares in the last quarter. Howard Capital Management raised its position in Pfizer by 1.4% in the first quarter. Howard Capital Management now owns 85,190 shares of the biopharmaceutical company’s stock valued at $2,525,000 after buying an additional 1,162 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. raised its position in Pfizer by 32.2% in the first quarter. Montrusco Bolton Investments Inc. now owns 14,769 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 3,599 shares in the last quarter. 69.66% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.305% during trading on Wednesday, hitting $33.029. The stock had a trading volume of 4,825,363 shares. The stock’s 50-day moving average price is $34.20 and its 200-day moving average price is $34.27. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The company has a market cap of $200.34 billion, a P/E ratio of 29.281 and a beta of 0.86.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the prior year, the business posted $0.56 earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
Several research analysts have recently commented on the company. Barclays PLC reiterated an “equal weight” rating and set a $34.00 price target on shares of Pfizer in a report on Tuesday, August 2nd. Sanford C. Bernstein set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $37.97 price target on the stock. in a report on Thursday, July 14th. Jefferies Group set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 1st. Finally, Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, July 25th. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.